Alnylam Pharmaceuticals, Inc. vs First Citizens BancShares Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $227.18 (market cap $30.39B), while First Citizens BancShares Inc trades at $2,270.44 (market cap $25.20B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and First Citizens BancShares Inc pays a 0.37% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | FCNCA | |
|---|---|---|
Market Cap | $30.39B | $25.20B |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $2.27K |
52-Week Low | $205.48 | $1.64K |
Enterprise Value | $28.35B | — |
Dividend Yield | — | 0.37% |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $227.12, up 2.68% in the last 24 hours, but technical indicators signal a bearish trend with resistance near $229. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with a net income of $313.75M, though recent Q2 2026 earnings missed estimates. Multiple law firms are investigating potential securities fraud, adding to negative sentiment.
Outlook is mixed: analyst consensus remains bullish with a $370.07 price target, but risks include ongoing legal probes, earnings volatility, and high valuation multiples. The stock faces near-term pressure from bearish technicals and investor caution despite solid fundamental progress.
First Citizens BancShares (FCNCA) trades at $2,271.31, up 0.81% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with a 12.19 P/E ratio, 25.23% net income margin, and consistent earnings beats in recent quarters. Recent business developments include expansion of commercial lending operations and strategic real estate acquisitions, supporting growth initiatives.
FCNCA presents a mixed outlook with strong earnings performance and reasonable valuation offset by cautious analyst sentiment. While technical indicators suggest continued upside potential, the 81.82% hold rating from analysts indicates concerns about valuation and deposit risks. Key opportunities include expanding commercial banking services, while risks center on net interest margin pressure and elevated uninsured deposits at 38.3%.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →